Financial Information and Governance

Latest Financial Results


Revenue for the three months ended March 31, 2024, was $5.7 million compared to $47.6 million for the same period in 2023


As of March 31, 2024, Adaptimmune had cash and cash equivalents of $140.7 million and Total Liquidity1 of $143.7 million, compared to $144.0 million and $146.9 million respectively, as of December 31, 2023

1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

For complete information regarding our financials, see our periodic filings

Balance Sheet

Includes Current Assets, Liabilities and Stockholder's Equity

View Balance Sheet

Income Statement

Includes Total Net Sales, Cost & Expenses and Earnings per share

View Income Statement

Cash Flow

Includes Net Income, Adjustments, and Cash flows from investing & financing activities

View Cash Flow